Catastrophic SLE with Rosai-Dorfman sinus histiocytosis:: successful treatment with anti-CD20/Rituximab

被引:46
作者
Petschner, F
Walker, UA
Schmitt-Gräff, A
Uhl, M
Peter, HH
机构
[1] Univ Freiburg Klinikum, Med Klin, Abt Rheumatol & Klin Immunol, Freiburg, Germany
[2] Univ Freiburg Klinikum, Inst Pathol, Freiburg, Germany
[3] Univ Freiburg Klinikum, Radiol Klin, Freiburg, Germany
关键词
D O I
10.1055/s-2001-17109
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
History and admission findings: A 59-year old woman was admitted with a four-month history of polyarthritis, myalgias and photosensitivity insufficiently responsive to methotrexate, corticosteroids and azathioprin. On physical examination she presented with symmetric ankle edema, polyserositis, petechial bleeding and swelling of cervical, axillary and inguinal lymph nodes. Investigations: Laboratory analysis revealed a trilinear cytopenia without signs of hemolysis. Acute phase proteins were elevated. Furthermore antinuclear antibodies, anti-phospholipid IgM antibodies, hypocomplementemia, a spurious IgG kappa paraprotein were noted. CT scans confirmed lymphadenopathy and revealed a pleural and pericardial effusion. Bone marrow biopsy. showed marked hypercellularity and polyclonal plasmocytosis. Based on these findings systemic lupus erythematosus was initially suspected. However when abdominal MRI showed a retroperitoneal mass, an extensive histological workup, which also included lymph nodes and spleen, revealed numerous plasma cells and histiocytes in dilated sinuses, diagnostic of Rosai-Dorfman sinus histiocytosis. Treatment and course: High dose corticosteroids, intravenous gamma-globulin and repeated courses of cyclophosphamide failed to improve the pancytopenia, as did splenectomy. The patient was given the anti-CD20 monoclonal antibody Rituximab and all signs and symptoms improved dramatically. 18 months after the last treatment, the patient is in complete clinical and hematological remission. Conclusions: Sinus histiocytosis of Rosai/Dorfman can be associated with or mimic severe SLE. Rituximab, an anti-CD20 monoclonal antibody, may improve the antibody-mediated pathogenetic mechanism underlying both entities.
引用
收藏
页码:998 / +
页数:4
相关论文
共 9 条
[1]   Non-Langerhans-cell histiocytosis [J].
Burgdorf, WHC ;
Zelger, B .
HAUTARZT, 1998, 49 (07) :600-613
[2]  
Coiffier B, 1998, BLOOD, V92, P1927
[3]   Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes [J].
Edwards, JCW ;
Cambridge, G .
RHEUMATOLOGY, 2001, 40 (02) :205-211
[4]  
FOUCAR E, 1990, SEMIN DIAGN PATHOL, V7, P19
[5]   The LE cell [J].
Hepburn, AL .
RHEUMATOLOGY, 2001, 40 (07) :826-827
[6]  
Kulemann JE, 2001, MED KLIN, V96, P287, DOI 10.1007/PL00002206
[7]  
ROSAI J, 1969, ARCH PATHOL, V87, P63
[8]   SPECIAL ARTICLE - THE 1982 REVISED CRITERIA FOR THE CLASSIFICATION OF SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
TAN, EM ;
COHEN, AS ;
FRIES, JF ;
MASI, AT ;
MCSHANE, DJ ;
ROTHFIELD, NF ;
SCHALLER, JG ;
TALAL, N ;
WINCHESTER, RJ .
ARTHRITIS AND RHEUMATISM, 1982, 25 (11) :1271-1277
[9]   PULSE CYCLOPHOSPHAMIDE TREATMENT OF LUPUS NEPHRITIS [J].
WITTE, T ;
SCHAUMANN, D ;
HEIN, R ;
HELMCHEN, U ;
NEUMANN, KH ;
KOCH, KM ;
DEICHER, H ;
SCHMIDT, RE .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1993, 118 (27-28) :1005-1010